So the market obviously does not see an opportunity for price appreciation in TRVN in the short term. Hence they are taking their money out in putting it in cyclical stocks.
I still have a good long term (1-3 yr) outlook for this stock and am still dollar cost averaging buying some every 2 weeks. But this isnt the only horse I have in the race.
I still believe the one year price target of 5 to $6 based on their potential sales ramp up.

Harley-Davidson’s new electric bikes look incredible — but they won’t be cheap.
Serial 1 Cycle will launch with four distinct models

I'm guessing that the short term pullback and "holding pattern" in TRVN is due to a few factors:
1. Market obsession with reentry into the popular market stocks and ETFs and need to generate capital for investing in those.
2. Shorting ease due to little/no TRVN news in near term.
3. Perceived relative lack of need for pipeline drug TRV027 now that Covid vaccines are becoming available.

At any rate, I'm looking at these as short term phenomena and price consolidation and am averaging in to take advantage while they are ramping up for OLINVYK promotion and/or BO.

Comments are always welcome for sanity check.

LONG TRVN
HerbieRay

I haven't heard anything.
B/O rumors are common in these Bios.
AMRN went through these for 2 years or more.
I'll keep my ears to the rail though.

HRS

These small biotechs with news only once in a while are very subject to shorting after their runups. If you believe in the company story, take a long term view. It's going to take them 2 or 3 quarters to develop any significant revenue and profit. I am looking out over 2 or 3 years and have been buying shares on a regular 2 week basis regardless of price.

Has TRVN published Q3 financials yet? I thought they were to be reporting on them Yesterday.

Bought a bunch at the uptrend line. Hope it holds!

I'm loving this consolidation part of the price. Buying shares on a 2 week regular basis regardless of price and looking out 2-3 years.

Well the 1 year (July/Aug 2021) price target is touted at $5-6. That s based on projected revenue ramp-up.

There is a lot of technical resistance around #3.10-#3.15 from early August selling that has to be overcome...gradually eaten away.

I;m looking forward to consolidating around these prices into December so I can get more $$$ to invest. After a couple of good quarterly financial reports, I expect this to take off for the target.

I have high hopes for the company, not just with their "O" drug, but for other drugs they have in early phase trials.

IF everything works out, we might get to $30-$50 in 2-3 years

Who thinks up this shit? Actually Hemp batteries are next generation. HOWEVER, this has little impact on ALYI who simply touts the industry news regardless if it has any real effect on ALYI performance.

They would tout improved paint if the industry came out with that.

They don't have any real positive real money or production to show for it, so they have to grab for straws.

I do a lot of chart studying. Not a pure technical trader, but I use volume bands and news as a guide. These is a lot of previous volume/resistance where the pullback occurred. Plus, after all the presentations were over, thee is usually a pullback.

I don't think we will break past that resistance until reasonable revenue growth is demonstrated. Maybe next quarter. Or more good news of some type.

All this is educated guesswork.

Its all good.
Sold 50% of shares. Will get back in if a pullback to around $2.60.
Looking for some other opportunities which are depressed right now.
GL!

Still holding on to my $1.63 shares. Ready to sell half up here around expected resistance @ approx $3.00. Expecting a pullback there. We'll see!
I'll also have fresh powder soon to buy even more on a pullback. Also looking at some others that have pulled back like TRVN did.

Its all good. GLTA

I'm looking far past the target, betting on price moves in anticipation of 2025 sales. Having experience with other small bios, I'm hoping they get a sales plan or partner or sell to a large bio with sales experience.

GLTA

Relatively new to this board and TRVN. I waited for some "confirmation" and got in at $1.63 average. I'm a long holder. I have to wait to get some fresh powder then get in more on a dip next week.

Next they'll be touting the chemical properties of the paint that they're using. They still have to start building and making at least a little bit of profit.

They'll keep putting out PRs until suckers on this board stop biting.

House of PAIN!

New to this board. The product sounded interesting so I'm trolling.

These "foriegn" ventures especially with odd financing are particularly suspect. 5 years ago Medify in the UK promoted a health records by cell phone system. Always a promise here and there. Sounded legit. Finally someone on the ihub board visited the office only to find an empty desk.

I lost a bundle.

This one is not for me. Risk/Reward way too high.I would rather invest in horseshoes LOL.

Your results may vary. This might be a Good "trading" gambit. Good luck.

BR:

The entrail trail gives you some idea of where the predators are!

Whal: ".... gambled on a very wide label"

How do you know this is fact am/or the cause of the delay?

Please understand, I am not trying to be obstinate or difficult here… I just want to know where this precious piece of info came out other than in speculation here. I try to read all posts but it is impossible on this board.

Thanes for your posts, I enjoy them.

HR

But will the ADCOM have access/knowledge of these things. Sure there are lots of great supporting items out there, but how will they influence the ADCOM if they don't know about them? Just Asking.

Just curious you think the Adcom would involve discussing the "orange" patent?

What could be more positive than that? Where are your expectations?
Just curious.

you may be right, but that will not happen in the short term that matters as it affects the upcoming Adcom and decision.

PS I'm a almost 80 year old still working for an engineer with General Dynamics because of issues that drained my financial resources in the past. AMRN is one of my bets to finance the rest of my years.

JL I asked if anybody had a summary of the Freedom of Information Act requests that Amarin put in. This was a response to my request if that's what you're getting at. I asked for my information only so I could bring myself up to speed on those requests.

How do we know Bhatt will be on the ADCOM?
Who determines the ADCOM composition?

Sam: How would you envision a question rigged for a NO vote for this ADCOM? Just curious.

Anyone?

The only "NO" I can legitimately see coming is one for a secondary indication which is perhaps weakly supported by the current study data, one which uses extrapolation. This would not include CV occurrences and deaths with trigs >150, a HUGE US market

HR

Thanks a whole bunch Flubber! Appreciated!

Time for some fun. Let's relook at the polling on the buyout estimates.

Regarding the Freedom of Information Act requests, could somebody please summarize what do you know about them or point me to a link that has that information thanks in advance.

I guess you're right. I was trying to make sense out of nonsense. Hopefully the conspiracy theories will prove false.

I've got some call options but they're January 2021

This wasn't retaliation. The FDA has had a whole lot of stuff thrown at them to digest over the last couple of months. I hate the delay but in view of all the recent events I don't think they had too many options. I think they're checking off all the squares so they won't get criticized for not doing their due job.

Could they possibly ask for another study to verify the mo issue before approval?

My take is that this adcom May likely benefit Us in the long term. Assuming we pass all the negatives will be have put to bed with undeniable oversight.

No I'm not a pump and dumper I am long Amarin and I'm hanging on to both my Amarin stock and some January 2021 20 and 25 strike calls.

So if its just a matter of optimum timing of starting advertising at issue, maybe this isn't as black and white as some here think. Perhaps the ads might stimulate some patient/doctor conversations, and these patients may still go for the scripts is spite of a higher cost.

I think JT might be overlapping some phases of his campaign in what he thinks is a likely optimum way.

JMO

That's my thinking too, however in a previous message, I asked if the dilution had an effect on TA support levels. I think I got a non-applicable answer.

HR